Bhlhb9 Inhibitors
Bhlhb9 inhibitors are a class of chemical compounds that specifically target the Bhlhb9 protein, a member of the basic helix-loop-helix (bHLH) family of transcription factors. Bhlhb9 is primarily involved in regulating gene expression by binding to specific DNA sequences, influencing a range of cellular processes including differentiation, development, and metabolic regulation. As a transcription factor, Bhlhb9 plays a critical role in controlling the expression of target genes, particularly those involved in neuronal function and cellular stress responses. Inhibitors of Bhlhb9 are designed to block its ability to bind to DNA or interact with other transcriptional machinery, thereby disrupting its regulatory functions and altering gene expression profiles. These inhibitors are valuable tools for understanding the role of Bhlhb9 in transcriptional networks and the molecular mechanisms underlying its activity in various cell types.
Bhlhb9 inhibitors are typically small molecules that bind to the DNA-binding domain or the protein-protein interaction surfaces of Bhlhb9, preventing it from effectively engaging with its target sequences on the genome. This inhibition results in the downregulation or misregulation of genes normally controlled by Bhlhb9, offering researchers insights into the specific pathways and cellular processes that depend on its activity. By selectively inhibiting Bhlhb9, researchers can study its role in cellular differentiation, particularly in neuronal cells, as well as its influence on broader transcriptional networks. These inhibitors are crucial for dissecting the biological functions of Bhlhb9, enabling detailed exploration of its contribution to cellular regulation and the dynamic control of gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
Alkylating agent disrupting DNA repair, indirectly inhibiting Bhlhb9. Interferes with MGMT-mediated repair, leading to DNA damage accumulation and affecting downstream pathways that modulate Bhlhb9 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway, indirectly affecting Bhlhb9. Inhibits AKT phosphorylation, impacting downstream signaling and altering the cellular environment that regulates Bhlhb9 expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor affecting the TGF-β pathway, indirectly influencing Bhlhb9. Blocks receptor activation, leading to downstream changes in gene expression that indirectly modulate Bhlhb9 levels. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
c-Jun N-terminal kinase (JNK) inhibitor disrupting the JNK pathway, indirectly impacting Bhlhb9. Modulates the phosphorylation of c-Jun, a downstream target, influencing Bhlhb9 expression indirectly through alterations in the JNK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor interfering with the JNK pathway, indirectly affecting Bhlhb9. Suppresses c-Jun phosphorylation, leading to downstream changes that modulate Bhlhb9 expression indirectly by influencing the JNK signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting the PI3K/AKT pathway, indirectly influencing Bhlhb9. Inhibits AKT activation, causing downstream changes that alter the cellular environment and modulate Bhlhb9 expression indirectly through the PI3K/AKT pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor disrupting the NF-κB pathway, indirectly impacting Bhlhb9. Blocks the activation of NF-κB, leading to downstream changes in gene expression that indirectly modulate Bhlhb9 levels by influencing the NF-κB pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor disrupting the MAPK pathway, indirectly influencing Bhlhb9. Suppresses phosphorylation cascades, altering the expression of SPRY4, a negative feedback regulator within the pathway that modulates Bhlhb9 indirectly. | ||||||
LY2090314 | 603288-22-8 | sc-507359 | 5 mg | $175.00 | ||
Glycogen synthase kinase 3 (GSK-3) inhibitor influencing the Wnt pathway, indirectly affecting Bhlhb9. Modulates β-catenin degradation, leading to downstream changes in gene expression that indirectly modulate Bhlhb9 levels by influencing the Wnt pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor disrupting the p38 MAPK pathway, indirectly affecting Bhlhb9. Suppresses the phosphorylation cascade, altering the expression of SPRY4, a negative feedback regulator within the pathway that modulates Bhlhb9 indirectly. | ||||||